Ranibizumab for Predominantly Classic Neovascular Age-related Macular Degeneration: Subgroup Analysis of First-year ANCHOR Results
Top Cited Papers
- 21 September 2007
- journal article
- research article
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 144 (6) , 850-857.e4
- https://doi.org/10.1016/j.ajo.2007.08.012
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Subgroup Analysis of the MARINA Study of Ranibizumab in Neovascular Age-Related Macular DegenerationOphthalmology, 2007
- Ranibizumab versus Verteporfin for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- THE ROLE OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN OCULAR HEALTH AND DISEASERetina, 2005
- Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1American Journal of Ophthalmology, 2003
- Basic Fibroblast Growth Factor and Vascular Endothelial Growth Factor Are Present in Epiretinal and Choroidal Neovascular MembranesAmerican Journal of Ophthalmology, 1996